wpostServer: http://css.washingtonpost.com/wpost
Robert H. Smith School of Business
The Motley Fool

Market Foolery Featured Podcasts

  • MarketFoolery 04.17.14
    When a company has legal problems, what does it mean for investors?  What does Yelp’s case before the Virginia State Supreme Court mean for Google and TripAdvisor?  And what does Adam Carolla’s legal battle mean for the future of the MarketFoolery podcast?  We tackle those questions and the exciting world of space law with Assistant General Counsel Chris Harris.
  • MarketFoolery: 04.16.2014
    We analyze the world of digital media, including Pandora, iTunes Radio, Spotify with Audiam CEO Jeff Price.  Plus, Jeff discusses how Netflix, Amazon, and many more are fighting in the “Battle for the Living Room”.
  • MarketFoolery 04.15.14
    We discuss the energy industry landscape, including Big Oil, natural gas, solar stocks and more with analyst Taylor Muckerman.  Plus we look at Chesapeake Energy one year after Aubrey McClendon left the CEO office.    
Capital Business
Posted at 10:21 AM ET, 06/08/2012

GlaxoSmithKline extends tender offer for Human Genome Sciences shares


The Human Genome Sciences Laboratories and Offices building in Rockville. (Jose Luis Magana - Reuters)
GlaxoSmithKline has extended its tender offer for the outstanding shares of Rockville-based Human Genome Sciences until June 29 as the British drugmaker pushes ahead with efforts to buy the company.

The tender offer for $13 a share was originally set to expire at midnight on June 7, but that deadline became untenable after HGS’s board of directors initiated a poison pill in hopes of derailing the hostile takeover.

The companies have been embroiled in a buyout dispute for nearly two months. Glaxo made an unsolicited bid for the company in April worth $2.6 billion, but that price was rejected because HGS officials said it undervalued the firm’s long-term financial prospects.

HGS urged its shareholders again on Friday to rebuke the tender offer and wait for the board of directors to complete a review process of its strategic alternatives that began in April.

“GSK declined to enter the process and, through its unsolicited tender offer, seeks to circumvent, disrupt and prematurely end the Company’s process to the disadvantage of HGS stockholders,” HGS said in a statement.

Some shareholders have filed a lawsuit claiming the board of directors has not acted in their best interest.

Glaxo and HGS are development partners on Benlysta, a drug that was approved by the Food and Drug Administration last March to treat systemic lupus. The companies have two other drugs in the pipeline, including one to treat cardiovascular disease.

By  |  10:21 AM ET, 06/08/2012

 
Read what others are saying
     

    © 2011 The Washington Post Company